Clinical pharmacology of long-acting β-receptor agonists

Life Sciences

Volumn 52, Issue 26, 1993, Pages 2161-2169

  Tattersfield, A E ^a  

^a NOTTINGHAM CITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; FORMOTEROL; METHACHOLINE; SALBUTAMOL; SALMETEROL;

ASTHMA; BRONCHODILATATION; CONFERENCE PAPER; DOSE TIME EFFECT RELATION; FORCED EXPIRATORY VOLUME; HUMAN; MUSCLE CRAMP; PRIORITY JOURNAL;

ADRENERGIC BETA-AGONISTS; ALBUTEROL; BRONCHODILATOR AGENTS; DRUG TOLERANCE; ETHANOLAMINES; HUMAN; TIME FACTORS;

EID: 0027256705     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/0024-3205(93)90730-Q     Document Type: Article

References (47)

1. Regular inhaled β-agonist treatment in bronchial asthma
2. Increased bronchial hyperresponsiveness after inhaling salbutamol during one year is not caused by subsensitisation to salbutamol
3. Changes in bronchial hyperreactivity induced by 4 weeks of treatment with anti-asthmatic drugs in patients with allergic asthma: a comparison between budesonide and terbutaline
4. Effect of long term treatment with inhaled corticosteroids and β-agonists on the bronchial responsiveness in children with asthma
5. Rebound increase in bronchial responsiveness after treatment with inhaled terbutaline
6. Evaluation of oral fenoterol in chronic asthmatic patients
7. 2-adrenoceptor agonist: comparison with salbutamol in adult asthmatic patients
8. A single dose comparison of inhaled albuterol and two formulations of salmeterol on airway reactivity in asthmatic subjects
9. 2-adrenergic receptor agonist: double blind comparison with salbutamol and placebo in children with asthma
10. Bronchodilator effect of inhaled formoterol vs salbutamol over 12 hours
11. Twelve hours' bronchodilating effect of inhaled formoterol in children with asthma: a double blind crossover study versus salbutamol
12. Time course of bronchodilating effect of inhaled formoterol, a potent and long acting sympathomimetic
13. Prolonged protection against methacholine-induced bronchoconstriction by the inhaled β-agonist formoterol
14. 2-adrenoceptor agonist
15. Duration of protection by inhaled salmeterol in exercise-induced asthma
16. 2-adrenergic agonist, has a longer blocking effect than albuterol on hyperventilation-induced bronchoconstrict
17. 2-adrenoceptor agonist
18. Paradoxical bronchoconstriction induced by vehicle in salmeterol metered dose inhaler
19. Salmeterol: a potent and long acting inhibitor of the release of inflammatory and spasmogenic mediators from human lung
20. Effects of N-aralkyl substitution of β-agonists on α- and β-adrenoceptor subtypes: pharmacological studies and binding assays
21. 2-adrenoceptor agonist: characterisation of pharmacological activity in vitro
22. 2-adrenoceptor agonist salmeterol in guinea-pig trachea
23. A study with cumulative doses of formoterol and salbutamol in children with asthma
24. Salmeterol: a dose response study with a long acting inhaled β-agonist [Abstract]
25. A placebo controlled comparison of the bronchodilator performance of salmeterol and salbutamol over 12 hours [Abstract]
26. Dose response study with high dose inhaled salmeterol in healthy subjects
27. Interaction and dose equivalence of salbutamol and salmeterol in patients with asthma
28. A way of looking at agonism and antagonism: Lessons from salbutamol, salmeterol and other β-adrenoceptor agonist
29. Comparison of cumulative and non-cumulative techniques to measure dose-response curves for β-agonists in patients with asthma
30. Anti-inflammatory effect of salmeterol of human alveolar macrophages
31. Protection against allergen-induced asthma by salmeterol
32. The inhibitory effect of nebulised albuterol on the early and late asthmatic reactions and increase in airway responsiveness provoked by inhaled allergen in asthma
33. 2-adrenergic agonist and a histamine H1-receptor antagonist on the late asthmatic response to inhaled antigen
34. 2-agonists in asthma
35. The influence of salmeterol xinafoate on mucosal inflammation in asthma
36. Late asthmatic reaction prevented by inhaled albuterol and formoterol
37. 2-agonist
38. Formoterol, a new long acting bronchodilator for inhalation
39. 2-agonist for inhalation twice daily, compared with salbutamol in the treatment of asthma
40. Inhaled salmeterol and salbutamol in asthmatic patients
41. Salmeterol: a four week study of a long acting β-adrenoceptor agonist for the treatment of reversible airways disease
42. A three-month comparison of twice daily inhaled formoterol versus four times daily inhaled albuterol in the management of stable asthma
43. Inhaled formoterol during one year in asthma: a comparison with salbutamol
44. The prolonged effects of salmeterol on airway hyperresponsiveness in asthma
45. Effects of a six week course of salmeterol on bronchial reactivity